SGI-1776

DB12494InvestigationalSmall molecule

SGI-1776 has been used in trials studying the treatment of Prostate Cancer, Non-Hodgkins Lymphoma, and Relapsed/Refractory Leukemias.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase pim-1, Serine/threonine-protein kinase pim-3, and Serine/threonine-protein kinase pim-2
Curator reviewed
Formula / weight: C₂₀H₂₂F₃N₅O · 405.425 g/mol (avg)
Code names: SGI-1776

Resolves to

Compound

Structure

InChIKeyMHXGEROHKGDZGO-UHFFFAOYSA-NSMILESCN1CCC(CNC2=NN3C(C=C2)=NC=C3C2=CC=CC(OC(F)(F)F)=C2)CC1

Targets

What you can answer from here — as of July 07, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with SGI-1776, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.